Experienced in Basal Cell Skin Cancer

Dr. Olivier Rixe

Hematology Oncology | Oncology
933 Bradbury Dr Se, Suite 2222, 
Albuquerque, NM 
Clinical Trials:Currently Recruiting for 4 Trials
Experienced in Basal Cell Skin Cancer
933 Bradbury Dr Se, Suite 2222, 
Albuquerque, NM 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Olivier Rixe is a Hematologist Oncology specialist and an Oncologist in Albuquerque, New Mexico. Dr. Rixe is rated as an Experienced provider by MediFind in the treatment of Basal Cell Skin Cancer. His top areas of expertise are Melanoma, Glioblastoma, Astrocytoma, and Glioma.

His clinical research consists of co-authoring 34 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Basal Cell Skin Cancer.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in OH
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

933 Bradbury Dr Se, Suite 2222, Albuquerque, NM 87106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2
A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors
A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors
Enrollment Status: Recruiting
Publish Date: September 16, 2025
Intervention Type: Drug
Study Drug: OBT076
Study Phase: Phase 1
A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)
A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)
Enrollment Status: Recruiting
Publish Date: April 07, 2023
Intervention Type: Drug
Study Drugs: DPX-Survivac, Pembrolizumab, CPA
Study Phase: Phase 2
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.
A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drug: Tumor Lysate, Particle-Loaded, Dendritic Cell Vaccine
Study Phase: Phase 2
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 02, 2024
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: May 01, 2023
Intervention Type: Drug
Study Drugs: SEA-CD40, Pembrolizumab, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 1
A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.
A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.
Enrollment Status: Active_not_recruiting
Publish Date: March 31, 2022
Intervention Type: Other, Drug
Study Drugs: Cyclophosphamide, Pembrolizumab
Study Phase: Phase 2
Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients With Advanced Solid Tumors and Recurrent High-Grade Gliomas
Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients With Advanced Solid Tumors and Recurrent High-Grade Gliomas
Enrollment Status: Completed
Publish Date: July 22, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
Enrollment Status: Completed
Publish Date: December 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Study of NLG802 for Adult Patients With Recurrent Advanced Solid Tumors
A Phase 1 Study of NLG802 for Adult Patients With Recurrent Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: June 04, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Window Study of Front-line Axitinib Followed by Axitinib and Radiation for Elderly Patients With Glioblastoma Multiforme (GBM)
A Phase II Window Study of Front-line Axitinib Followed by Axitinib and Radiation for Elderly Patients With Glioblastoma Multiforme (GBM)
Enrollment Status: Terminated
Publish Date: September 19, 2017
Intervention Type: Drug, Radiation
Study Phase: Phase 2
A Dose Escalation, Single Arm, Phase 1b-2 Combination Study of BEZ235 With Everolimus to Determine the Safety, Pharmacodynamics and Pharmacokinetics in Subjects With Advanced Solid Malignancies
A Dose Escalation, Single Arm, Phase 1b-2 Combination Study of BEZ235 With Everolimus to Determine the Safety, Pharmacodynamics and Pharmacokinetics in Subjects With Advanced Solid Malignancies
Enrollment Status: Terminated
Publish Date: August 23, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 13 Less Clinical Trials

34 Total Publications

Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan.
Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan.
Journal: The oncologist
Published: December 22, 2024
Similar Doctors
Experienced in Basal Cell Skin Cancer
Dr. Scott Herbert
Hematology Oncology | Oncology | Hematology
Experienced in Basal Cell Skin Cancer
Dr. Scott Herbert
Hematology Oncology | Oncology | Hematology

Nexus Health

2085 S Pacheco St, 
Santa Fe, NM 
 (55.5 miles away)
505-670-8292
Languages Spoken:
English
See accepted insurances

Scott Herbert is a Hematologist Oncology specialist and an Oncologist in Santa Fe, New Mexico. Dr. Herbert is rated as a Distinguished provider by MediFind in the treatment of Basal Cell Skin Cancer. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Familial Colorectal Cancer, Large-Cell Immunoblastic Lymphoma, and Colorectal Cancer.

Experienced in Basal Cell Skin Cancer
Dr. Ian Rabinowitz
Hematology | Oncology
Experienced in Basal Cell Skin Cancer
Dr. Ian Rabinowitz
Hematology | Oncology
Unm Cancer Ctr, 1201 Camino De Salud Ne, 
Albuquerque, NM 
 (1.7 miles away)
505-272-4946
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients

Ian Rabinowitz is a Hematologist and an Oncologist in Albuquerque, New Mexico. Dr. Rabinowitz is rated as a Distinguished provider by MediFind in the treatment of Basal Cell Skin Cancer. His top areas of expertise are Ependymoma, Embryonal Tumor with Multilayered Rosettes, Neuroepithelioma, and Atypical Teratoid Rhabdoid Tumor (ATRT). Dr. Rabinowitz is currently accepting new patients.

Experienced in Basal Cell Skin Cancer
Dr. Ala E. Ebaid
Hematology | Oncology
Experienced in Basal Cell Skin Cancer
Dr. Ala E. Ebaid
Hematology | Oncology

Unm Medical Group Inc

2211 Lomas Blvd Ne, 
Albuquerque, NM 
 (1.4 miles away)
505-272-2111
Languages Spoken:
English
See accepted insurances

Ala Ebaid is a Hematologist and an Oncologist in Albuquerque, New Mexico. Dr. Ebaid is rated as an Experienced provider by MediFind in the treatment of Basal Cell Skin Cancer. His top areas of expertise are Systemic Mastocytosis, Essential Thrombocythemia, Antiphospholipid Syndrome, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rixe's expertise for a condition
ConditionClose
    View All 16 Advanced Conditions
    View All 69 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile